Cargando…
UDCA in UC: A true disease modifier or symptoms reliever?
Autor principal: | Sulais, Eman Al |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448015/ https://www.ncbi.nlm.nih.gov/pubmed/34380866 http://dx.doi.org/10.4103/sjg.sjg_228_21 |
Ejemplares similares
-
Diagnostic delay of pediatric inflammatory bowel disease in Saudi Arabia—the community, the physicians, and the disease: Where's the hold-up?
por: Sardi, Mais Al, et al.
Publicado: (2019) -
Differential effects of norUDCA and UDCA in obstructive cholestasis in mice
por: Fickert, Peter, et al.
Publicado: (2013) -
Glyceric Prodrug of Ursodeoxycholic Acid (UDCA): Novozym 435-Catalyzed Synthesis of UDCA-Monoglyceride
por: Zappaterra, Federico, et al.
Publicado: (2021) -
Response to A Al-Judaibi et al.: Barriers to research productivity among physicians in Saudi Arabia: Taking a deep dive into the world of academia
por: Al sahafi, Majid, et al.
Publicado: (2021) -
Letter to the editor UC-II® Undenatured type II collagen: update to analytical methods
por: Lugo, James P.
Publicado: (2019)